Ascendis Pharma AS (ASND)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $18.06B
Last updated: Nov 17, 2026 at 11:05 AM ET
Ascendis Pharma AS (ASND) Financials: Revenue, Profit and Cash Flow
Ascendis Pharma AS reported revenue of EUR 691.71M for the fiscal year ended Dec 31, 2025, up 90.2% from the year before. That year, net income was EUR -219.03M with a net margin of -31.7%, operating cash flow was EUR 51.77M and free cash flow was EUR 43.62M. The quarter ended Sep 30, 2026 had revenue of EUR 367.46M and net income of EUR 73.53M.
Revenue and Margins
The operating margin was -18.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from EUR 4.61M, a compound annual rate of 74.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 691.71M | +90.2% | 85.1% | -18.9% | -31.7% |
| Dec 2024 | 363.64M | +36.3% | 87.8% | -76.7% | -104.0% |
| Dec 2023 | 266.72M | +421.2% | 83.4% | -170.8% | -180.5% |
| Dec 2022 | 51.17M | +557.9% | 76.3% | -1097.9% | -1139.6% |
| Dec 2021 | 7.78M | +11.9% | 54.7% | -5808.6% | -4931.6% |
| Dec 2020 | 6.95M | -48.0% | 100.0% | -4755.1% | -6025.5% |
| Dec 2019 | 13.38M | +26.4% | 100.0% | -1695.1% | -1630.0% |
| Dec 2018 | 10.58M | +591.6% | 100.0% | -1462.6% | -1229.5% |
| Dec 2017 | 1.53M | -66.8% | 100.0% | -7290.3% | -8097.8% |
| Dec 2016 | 4.61M | N/A | 100.0% | -1583.2% | -1487.3% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 691.71M | 363.64M | 266.72M | 51.17M | 7.78M | 6.95M | 13.38M | 10.58M | 1.53M | 4.61M |
| Cost of revenue | 103.18M | 44.26M | 44.40M | 12.14M | 3.52M | 0 | 0 | 0 | N/A | N/A |
| Gross profit | 588.53M | 319.38M | 222.32M | 39.04M | 4.25M | 6.95M | 13.38M | 10.58M | 1.53M | 4.61M |
| Research and development | 283.50M | 307.00M | 413.45M | 379.62M | 295.87M | 260.90M | 191.62M | 140.28M | 99.59M | 66.02M |
| Operating income | -130.89M | -278.76M | -455.54M | -561.81M | -451.79M | -330.62M | -226.72M | -154.76M | -111.54M | -72.92M |
| Net income | -219.03M | -378.08M | -481.45M | -583.19M | -383.58M | -418.95M | -218.02M | -130.10M | -123.90M | -68.50M |
| EBITDA | -109.80M | N/A | -411.17M | -529.18M | -364.64M | N/A | -210.34M | -129.48M | N/A | -68.05M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 367.46M | 344.90M | 250.66M | 245.18M | 213.63M | 158.04M | 100.95M | 173.92M | 57.83M | 36.00M | 95.89M | 137.70M |
| Gross profit | 335.16M | 312.61M | 229.03M | 217.98M | 191.28M | 126.60M | 83.44M | 159.89M | 46.63M | 24.53M | 88.33M | 118.25M |
| Operating income | 123.84M | 63.43M | 25.22M | 9.80M | 11.00M | -52.95M | -104.21M | 383.00K | -96.74M | -133.26M | -49.15M | -36.61M |
| Net income | 73.53M | 210.40M | 639.69M | -33.25M | -60.99M | -38.85M | -94.63M | -38.47M | -99.20M | -109.38M | -131.03M | -86.88M |
Balance Sheet
As of Dec 2025, total debt of EUR 871.58M exceeded cash and equivalents by 255.80M. Shareholder equity was negative, at -162.75M, as total liabilities of 1.46B exceeded total assets of 1.30B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.30B | 1.18B | 825.59M | 1.09B | 1.08B | 979.79M | 676.73M | 318.97M | 210.98M | 190.07M |
| Current assets | 1.11B | 1.06B | 702.72M | 923.47M | 805.89M | 740.13M | 611.17M | 292.91M | 204.63M | 183.96M |
| Cash and equivalents | 615.78M | 559.54M | 392.16M | 444.77M | 446.27M | 584.52M | 598.11M | 277.86M | 195.35M | 180.33M |
| Total liabilities | 1.46B | 1.29B | 971.28M | 826.39M | 201.29M | 141.08M | 79.62M | 38.92M | 23.77M | 13.46M |
| Short-term debt | 486.32M | 491.54M | 435.44M | 426.77M | 13.99M | 6.86M | 5.90M | 0 | 0 | 0 |
| Long-term debt | 385.25M | 365.08M | 534.25M | 482.96M | 97.97M | N/A | 0 | 0 | 0 | 0 |
| Shareholder equity | -162.75M | -105.71M | -145.70M | 263.35M | 883.63M | 838.71M | 597.11M | 280.05M | 187.21M | 176.61M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2.47B | 2.29B | 2.01B | 1.30B | 1.15B | 1.09B | 1.06B | 1.18B | 1.09B | 758.30M | 802.50M | 825.59M |
| Total liabilities | 942.42M | 849.18M | 1.52B | 1.46B | 1.33B | 1.28B | 1.25B | 1.29B | 1.19B | 1.08B | 1.04B | 971.28M |
| Cash and equivalents | 980.69M | 811.92M | 573.42M | 615.78M | 539.09M | 494.05M | 517.92M | 559.54M | 625.51M | 258.70M | 320.24M | 392.16M |
| Shareholder equity | 1.53B | 1.44B | 488.48M | -162.75M | -174.07M | -187.57M | -189.81M | -105.71M | -97.32M | -321.13M | -238.18M | -145.70M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 84.3% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 51.77M | -306.20M | -467.36M | -495.70M | -417.65M | -271.55M | -175.94M | -138.80M | -95.10M | -60.18M |
| Capital expenditures | 8.15M | 1.43M | 2.44M | 14.49M | 24.23M | 21.55M | 5.16M | 2.65M | 941.00K | 672.00K |
| Free cash flow | 43.62M | -307.62M | -469.80M | -510.19M | -441.88M | -293.10M | -181.09M | -141.45M | -96.04M | -60.85M |
| Dividends paid | N/A | N/A | N/A | 5.06M | 33.14M | N/A | 0 | 0 | 0 | 0 |
| Investing cash flow | -8.15M | 6.88M | 286.47M | 61.73M | -110.58M | -291.20M | -5.16M | -2.65M | -941.00K | -672.00K |
| Financing cash flow | 34.89M | 443.93M | 134.29M | 396.77M | 351.39M | 602.65M | 493.59M | 203.27M | 124.72M | 117.46M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 184.70M | 286.35M | -7.85M | 70.67M | 2.15M | -7.34M | -14.31M | -87.18M | -56.13M | -61.31M | -101.58M | -42.47M |
| Capital expenditures | 2.63M | 3.24M | 7.84M | 3.30M | 53.00K | 4.34M | 703.00K | 383.00K | 467.00K | 342.00K | 199.00K | 63.00K |
| Free cash flow | 182.07M | 283.11M | -15.69M | 67.37M | 2.10M | -11.68M | -15.02M | -87.56M | -56.60M | -61.65M | -101.78M | -42.53M |
Frequently Asked Questions About ASND
What is Ascendis Pharma AS's annual revenue?
Ascendis Pharma AS reported revenue of EUR 691.71M for the fiscal year ended Dec 31, 2025.
How fast is Ascendis Pharma AS's revenue growing?
Revenue was up 90.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 138.2%.
Is Ascendis Pharma AS profitable?
No. Ascendis Pharma AS reported net income of EUR -219.03M for the fiscal year ended Dec 31, 2025, with a net margin of -31.7%.
How much free cash flow does ASND generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of EUR 51.77M minus capital expenditures of EUR 8.15M produced free cash flow of EUR 43.62M.
How much debt does Ascendis Pharma AS have?
The balance sheet dated Dec 31, 2025 reported long-term debt of EUR 385.25M, short-term debt of EUR 486.32M and cash and equivalents of EUR 615.78M.
ASND pages: Overview, Financials, Valuation, Competitors